JP2005527470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527470A5 JP2005527470A5 JP2003524606A JP2003524606A JP2005527470A5 JP 2005527470 A5 JP2005527470 A5 JP 2005527470A5 JP 2003524606 A JP2003524606 A JP 2003524606A JP 2003524606 A JP2003524606 A JP 2003524606A JP 2005527470 A5 JP2005527470 A5 JP 2005527470A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nesp
- methionine
- concentration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/945,517 US20030104996A1 (en) | 2001-08-30 | 2001-08-30 | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| PCT/US2002/027855 WO2003020299A1 (en) | 2001-08-30 | 2002-08-29 | L-methionine as a stabilizer for nesp/epo in hsa-free formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010052203A Division JP2010138195A (ja) | 2001-08-30 | 2010-03-09 | Ｈｓａ非含有組成物中のｎｅｓｐ／ｅｐｏの安定化剤としてのｌ−メチオニン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005527470A JP2005527470A (ja) | 2005-09-15 |
| JP2005527470A5 true JP2005527470A5 (https=) | 2006-10-05 |
| JP4493334B2 JP4493334B2 (ja) | 2010-06-30 |
Family
ID=25483206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524606A Expired - Lifetime JP4493334B2 (ja) | 2001-08-30 | 2002-08-29 | Ｈｓａ非含有組成物中のｎｅｓｐ／ｅｐｏの安定化剤としてのｌ−メチオニン |
| JP2010052203A Pending JP2010138195A (ja) | 2001-08-30 | 2010-03-09 | Ｈｓａ非含有組成物中のｎｅｓｐ／ｅｐｏの安定化剤としてのｌ−メチオニン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010052203A Pending JP2010138195A (ja) | 2001-08-30 | 2010-03-09 | Ｈｓａ非含有組成物中のｎｅｓｐ／ｅｐｏの安定化剤としてのｌ−メチオニン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030104996A1 (https=) |
| EP (1) | EP1439848B1 (https=) |
| JP (2) | JP4493334B2 (https=) |
| KR (1) | KR100596610B1 (https=) |
| CN (1) | CN100384468C (https=) |
| CA (1) | CA2458386C (https=) |
| MX (1) | MXPA04001774A (https=) |
| PL (1) | PL374122A1 (https=) |
| TW (1) | TWI327068B (https=) |
| WO (1) | WO2003020299A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| US8796206B2 (en) * | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| AU2009210741A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| PE20110543A1 (es) | 2008-08-15 | 2011-08-04 | Ironwood Pharmaceuticals Inc | Formulacion solida oral que comprende linaclotida, cation de calcio y leucina |
| CN103599541A (zh) * | 2008-09-10 | 2014-02-26 | 弗·哈夫曼-拉罗切有限公司 | 用于防止蛋白质氧化降解的组合物和方法 |
| CA2765220A1 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| CA2770077A1 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| FR2954325B1 (fr) | 2009-12-23 | 2012-02-03 | Flamel Tech Sa | Polymere amphiphile fonctionnalise par la methionine |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| PT2525787T (pt) | 2010-01-19 | 2017-12-18 | Hanmi Science Co Ltd | Formulações líquidas para conjugado de g-csf de longa ação |
| EP2364690A1 (en) * | 2010-02-12 | 2011-09-14 | Centro De Ingenieria Genetica Y Biotecnologia | Orally administrable pharmaceutical pellet of epidermal growth factor |
| UA108636C2 (xx) | 2010-02-17 | 2015-05-25 | Пептид | |
| EP2603232B1 (en) | 2010-08-11 | 2019-09-25 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| MX347354B (es) | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | Tratamientos para trastornos gastrointestinales. |
| CN108771655A (zh) | 2011-10-28 | 2018-11-09 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| EP2974734B1 (en) | 2013-03-12 | 2018-10-10 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
| EP2968468B1 (en) * | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| AU2014229282B2 (en) | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| BR122020004385B1 (pt) * | 2014-01-13 | 2022-10-04 | Amgen Inc | Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| RU2599031C1 (ru) * | 2015-08-11 | 2016-10-10 | Общество с ограниченной ответственностью "АйВиФарма" | Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты) |
| JP7046814B2 (ja) * | 2015-12-30 | 2022-04-04 | ジェネンテック， インコーポレイテッド | タンパク質製剤のためのトリプトファン誘導体の使用 |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| US11338018B2 (en) | 2016-12-19 | 2022-05-24 | Harrow Ip, Llc | Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof |
| JP6172880B1 (ja) * | 2017-02-01 | 2017-08-02 | 協和発酵キリン株式会社 | ダルベポエチンを含む液体医薬組成物 |
| US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
| CN111278453A (zh) | 2017-09-07 | 2020-06-12 | Jcr制药股份有限公司 | 水性药物组合物 |
| EP3833382A1 (en) * | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| CN119857138A (zh) * | 2018-09-13 | 2025-04-22 | 豪夫迈·罗氏有限公司 | Csf-1r抗体制剂 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| CN118338910A (zh) * | 2021-12-03 | 2024-07-12 | 杰科（天津）生物医药有限公司 | 一种制剂及其制备方法和应用 |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4667016A (en) * | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS6297229A (ja) * | 1985-10-21 | 1987-05-06 | Nec Kansai Ltd | 螢光膜の形成方法 |
| US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| TW497972B (en) * | 1995-06-08 | 2002-08-11 | Kirin Brewery | Stable thrombopoietin (TPO)-containing lyophilized compositions |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| AU1226901A (en) * | 1999-10-22 | 2001-05-08 | Amgen, Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
-
2001
- 2001-08-30 US US09/945,517 patent/US20030104996A1/en not_active Abandoned
-
2002
- 2002-08-29 TW TW091119907A patent/TWI327068B/zh not_active IP Right Cessation
- 2002-08-29 CN CNB028217098A patent/CN100384468C/zh not_active Expired - Lifetime
- 2002-08-29 JP JP2003524606A patent/JP4493334B2/ja not_active Expired - Lifetime
- 2002-08-29 PL PL02374122A patent/PL374122A1/xx not_active Application Discontinuation
- 2002-08-29 CA CA2458386A patent/CA2458386C/en not_active Expired - Lifetime
- 2002-08-29 KR KR1020047002971A patent/KR100596610B1/ko not_active Ceased
- 2002-08-29 WO PCT/US2002/027855 patent/WO2003020299A1/en not_active Ceased
- 2002-08-29 MX MXPA04001774A patent/MXPA04001774A/es active IP Right Grant
- 2002-08-29 EP EP02766203.0A patent/EP1439848B1/en not_active Expired - Lifetime
-
2010
- 2010-03-09 JP JP2010052203A patent/JP2010138195A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527470A5 (https=) | ||
| CA2458386A1 (en) | L-methionine as a stabilizer for nesp/epo in hsa-free formulations | |
| ES2526707T3 (es) | Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos | |
| RU2113845C1 (ru) | Водный раствор интерферона | |
| JP2005537234A5 (https=) | ||
| CA2275890A1 (en) | Stable liquid interferon formulations | |
| AU2003228962A1 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| DE60035337D1 (de) | Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken | |
| CY1115918T1 (el) | Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη | |
| ATE460155T1 (de) | Pharmazeutische zusammensetzung mit lyophilisiertem rekombinantem faktor viii ohne albumin als stabilisator | |
| JPS6021570B2 (ja) | ド−パ類の高濃度製剤の製法 | |
| CY1110106T1 (el) | Φαρμακοτεχνικες μορφες για την παρατεταμενη απελευθερωση ιντερφερονων και θεραπευτικες εφαρμογες αυτων | |
| IT1187828B (it) | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi | |
| JPS59181224A (ja) | 安定なインタ−フエロン製剤の製法 | |
| DE3777845D1 (de) | Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. | |
| BRPI0414157A (pt) | polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo | |
| JP2004534073A5 (https=) | ||
| DE69315388D1 (de) | Aus bakteriellen Proteinen bestehender Extrakt, Verfahren zur dessen Herstellung und diesen Extrakt enthaltende pharmazeutische Zusammensetzung | |
| KR950024769A (ko) | 고농도 tcf 제제 | |
| KR890003409A (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
| JP2004538275A5 (https=) | ||
| KR930012023A (ko) | 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 | |
| ATE331735T1 (de) | Verfahren zur monomerisierung von humanen serumalbumin-polymeren | |
| RU2238758C2 (ru) | Водный раствор интерферона-альфа-два человека для инъекций | |
| CN101757612A (zh) | 一种鸡用γ-干扰素高效注射液及其制备方法 |